Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
“Cytokine storm”, not only in COVID-19 patients. Mini-review

Norbert Lukan *

IV-th Department of Medicine, Safarik University, Kosice, Slovakia

ARTICLE INFO

Keywords:
Cytokine storm
Cytokine release syndrome
Treatment

ABSTRACT

Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient’s death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs.

Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients.

Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm.

Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.

1. Introduction

Although to date, “cytokine storm” is mainly connected to COVID-19, many hypothesis concerning treatment modalities have been rising in the last fifteen years. It seems to be important to put together knowledge about known immunological mechanisms and the contemporary medicaments (except for antimicrobial drugs without immunomodulatory effect) which are potent to modulate immunologic answer even to fight against such a harmful process. A recent PubMed search for cytokine storm or cytokine release syndrome yielded 1102 and 1817 hits respectively; over 100 articles/year were within the past five years.

Cytokine release syndrome (CRS) or “cytokine storm” is a form of uncontrolled systemic inflammatory reaction that can be triggered by a variety of factors. It starts fairly quickly in cases of severe (mainly respiratory) infections, in other types of massive immune activation such as transplantation [1] or administration of drugs. It can be frequently mentioned in connection to medical interventions such as transplantation [1] or administration of certain drugs (monoclonal antibodies, adoptive T-cell therapies) [2]. Subtle CRS may occur following immunization against rubella, human papillomavirus, or hepatitis B [3].

The term “cytokine release syndrome” appeared in the early ’90 s, when the anti T-cell antibody muromonab-CD3 was introduced as an immunosuppressive treatment for solid organ transplantation [4]. Yet, Vegh et al. as early as in 1975 observed that by administering polyclonal antibodies the possibility of systemic anaphylactic reactions and other side effects may be present [5]. Presumably they supposed a cytokine-storm like reaction which has different phenotypes from the classical type-I or complement-mediated reaction. At that time such biomarkers as tryptase, IL-6, bradykinin etc. were not known or were on the early stages of immunological research [6].

Except for anti-thymocyte globulins [7,8], CRS has been described after administration of several antibody-based therapies such as rituximab [9], alemtuzumab [10], muromonab [4], theralizumab [11], nivolumab [12], obinutuzumab [13], brentuximab [14]. Anticancer non-protein-based treatment with oxaliplatin [15] and IMiDs (lenalidomide) [16] can activate cytokine storm as well. Furthermore, CRS was reported in stem cell transplantation and graft-versus-host disease. As mentioned above, cytokine storm is also a proposed pathomechanism of severe viral infections due to massive T cell stimulation. It is supposed to be combined with all influenza epidemics since Spanish flu in 1919 through dengue, Ebola to corona virus infection in 2020 [17]. CRS has

* Correspondence to: IV-th Department of Medicine, Faculty of Medicine, Safarik University, Rastislavova 43, 04001, Kosice, Slovakia.
E-mail address: norbertlukan@gmail.com.

https://doi.org/10.1016/j.imlet.2020.09.007
Received 8 July 2020; Received in revised form 10 September 2020; Accepted 22 September 2020
Available online 29 September 2020
0165-2478/© 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
been observed also in surgical patients with severe bacterial infections or in patients with inhalation injury [18].

Such broad spectrum of etiological factors leading to clinical and laboratory manifestation of CRS like hypotension, hypoxia, fever, fatigue, myalgias, malaise, nausea, hypoxia, coagulopathy, capillary leakage, tachycardia, tachypnea, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, organ toxicity, pulmonary edema, pneumonitis, and renal insufficiency support the basic scientific postulate: cytokine storm results from excessive pro-inflammatory stimuli, inadequate regulation of inflammation, immune cells or both [19]. Not only pro-inflammatory cytokines, but also anti-inflammatory cytokines appear in circulating blood, such as IL-10 and transforming growth factor-beta (TGF-beta). Cytokines work in counterbalance mode, as demonstrated on typical example: products of the Th2 immune response suppress the Th1 immune response and vice versa [20]. In a case of robust activation of immune balance, without the ability to resolve the inflammation, the collateral damage to surrounding cells can be catastrophic, resulting in septic shock, multiple organ dysfunction, immunosuppression and even death [21]. If the inflammatory response is properly regulated, regulatory mechanisms prevent the body from being damaged by systemic inflammation caused by sudden activation of cytokine release. Such inflammation can be resolved effectively, with little or no long-term damage to the host [22].

If CRS is primarily caused by environmental case, there is a strong request to allow restoration of homeostasis. Offending microbe, allergen, or cytotoxic agent when possible, should be eliminated. Anti-microbial treatment is indicated in any form of cytokine storm if contributing pathogen is suspected. Even though simultaneous antimicrobial treatment is not the topic of presented contribution, many of contemporary molecules have, except for their antimicrobial potency, also anti-inflammatory and immunomodulatory effect.

Canna and Behrens [19] propose a conceptual model of various cytokine release syndromes based on the nature of mechanisms of inflammation. Careful assessment of host and environmental factors strengthen the idea of rational therapeutic approach. In a case of host dependent mechanism of inflammation, they emphasize the use of cytotoxic agents while in a case of environmentally induced inflammation (infection) antimicrobials are predominately indicated. Data about cytokine storm in human anaphylaxis or other severe allergic (drug) reactions are scarce [23]. Even if all forms of cytokite release syndrome induced by environmental or host factors arrive at their final common pathway, the critical point is to understand and specify the exact mechanism directing more precise mode of treatment.

The clinical picture of cytokine storm slightly varies in its several forms, but generally manifests as “overlap syndrome” laboratory manifesting in decreasing cell counts, decreasing ESR, increased ferritin level, NK dysfunction, and hemophagocytosis [19]. Although the primary cause of CRS is crucial to understand for restoring immunologic balance, the main focus in treatment should be directed towards final common pathway. At that level, influence on all pro-inflammatory and anti-inflammatory humoral and/or cellular compounds might have been considered. When activating intense inflammatory pathways through immune cells, endothelium, bone marrow, liver and kidney, a vicious circle of harmful processes can lead to death. Immunopathology could also be associated with extensive microthrombosis mostly in lungs, thus ischemic/reperfusion injury contributes to broadening of immune mediated inflammation [24]. Therefore, multilevel treatment opportunities should be a challenge (Fig. 1).

Clinical picture of CRS or cytokine storm strikes suddenly and the main goal, after starting intensive care treatment and targeting the elimination environmental trigger (if possible), is to administer potential drugs capable of controlling cytokine production and its harmful effect. Excessive cytokine production by immunomodulatory drugs has its place on top of contemporary research. From web portal “ClinicalTrials.gov” 27 studies under key words cytokine release syndrome and 32 studies under cytokine storm were analyzed (last accessed 26 August 2020). Out of those trials, not all deal with immunomodulators. Studies involved in the text are summarized in Table 1. Three studies are completed, two of them have already been published [25,26].

![Fig. 1. Vicious circle of cytokine storm in a view of causes, course and treatment. (HLH - hemophagocytic lymphohistiocytosis, MAS - macrophage activation syndrome, SIRS - systemic inflammatory response syndrome, NAC – N-acetylcysteine).](image-url)
### Table 1
Summary of cited clinical trials.

| Study title                                                                 | Status | Identification number | Location           | Phase* |
|-----------------------------------------------------------------------------|--------|-----------------------|--------------------|--------|
| Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation (CYCOV) | R      | NCT04324528           | Freiburg, Germany  | 1/2    |
| Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation (CYCOV-II) | IP     | NCT04385771           | Freiburg, Germany  | 1/2    |
| Early Haemadsorption in Major Burns Adsortion of Cytokines Early in Septic Shock: the ACESS Study | C      | NCT02288975           | Szeged, Hungary    | 1/2    |
| Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation (CYTER) | R      | NCT03685383           | Freiburg, Germany  | 1/2    |
| Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS) (CYTERLEASE) | IP     | NCT04048434           | Hannover, Germany  | 1/2    |
| Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic Shock | R      | NCT03974386           | Taipei, Taiwan     | 1/2    |
| Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19 (COVID-19-BHBO) | R      | NCT04327505           | Gelsenkirchen, Regensburg, Germany*** Bielefeld, Germany*** | 1/2    |
| Efficacy and Safety of Tocilizumab in the Treatment of SARS-CoV-2 Related Pneumonia (TOSCA) | R      | NCT04332913           | L’Aquila, Italy    | 1/2    |
| Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation | R      | NCT03533101           | Monterrey, ** Mexico    | 1/2    |
| Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome | IP     | NCT02906397           | Philadelphia (PA), US | 1/2    |
| Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) (RUXCOVID) Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection (RESPIRE) Treatment of SARS Caused by COVID-19 With Ruxolitinib Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) Baricitinib Therapy in COVID-19 Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome (COVIDIOL) The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA) | R      | NCT04361903           | Pisa, Italy     | 1/2    |
|                             | IP     | NCT04334044           | Huixquilucan, Mexico | 1/2    |
|                             | IP     | NCT04320277           | Prato, Italy        | 1/2    |
|                             | R      | NCT04358614           | Prato, Italy        | 2/3    |
|                             | R      | NCT01752348           | Aarhus C, Denmark   | Phase 2|
|                             | IP     | NCT04366908           | Córdoba, Spain      | Phase 2|
|                             | R      | NCT04458298           | Multicentric (5 centers), US | Phase 2|

(* – if applicable, ** – active, but recruitment interrupted in 2018, *** – only Swedish center started to recruit, IP – in preparation, R – recruited, C – completed).

### Table 1 (continued)

| Study title                                                                 | Status | Identification number | Location          | Phase* |
|-----------------------------------------------------------------------------|--------|-----------------------|-------------------|--------|
| Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) (RUXCOVID) Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection (RESPIRE) Treatment of SARS Caused by COVID-19 With Ruxolitinib Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) Baricitinib Therapy in COVID-19 Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome (COVIDIOL) The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA) | IP     | NCT04361903           | Pisa, Italy     | 1/2    |
|                             | IP     | NCT04334044           | Huixquilucan, Mexico | 1/2    |
|                             | IP     | NCT04320277           | Prato, Italy        | 1/2    |
|                             | R      | NCT04358614           | Prato, Italy        | 2/3    |
|                             | C      | NCT01752348           | Aarhus C, Denmark   | Phase 2|

(– if applicable, ** – active, but recruitment interrupted in 2018, *** – only Swedish center started to recruit, IP – in preparation, R – recruited, C – completed).

## 2. Management of cytokine storm

### 2.1. Haemadsorption

Seven of these studies are focused on using haemadsorption in CRS management caused by SARS-CoV-2 (NCT04324528, NCT04385771), in severe burns (NCT04195126), septic shock (NCT02288975), cardiac arrest (NCT03685383) and after CAR-T cell therapy (NCT04048434). Haemadsorption can lead to a reduction of the circulating pro- and anti-inflammatory cytokines and thus improve the course of the disease and the outcome of patients. One of them (NCT03974386) recruits patients with sepsis to establish influence of environmentally induced inflammation caused by gram-negative bacterial endotoxin as the main trigger for systemic inflammatory reaction. Endotoxin binds to Toll-like receptor 4 (TLR4) and so induces a cytokine storm. The amount of endotoxin is associated with shock, insufficient intestinal perfusion, and poor prognosis. Therefore, haemadsorption can antagonize the action of endotoxin reducing the cytokine storm and inflammatory response to...
improve the prognosis of sepsis.

2.2. Hyperbaric oxygen

One study (NCT04327505) is focused on efficacy of hyperbaric oxygen which significantly reduces inflammatory cytokines. It is expected to be effective in the treatment of cytokine storm in viral infections (SARS-CoV-2). It is possible to suppose that a clinical effect of hyperbaric oxygen is caused by immunological factors. The effect on monocytes may be the basis for reduced levels of circulating pro-inflammatory cytokines under stress conditions [27]. Apparently, hyperbaric oxygen could influence inflammation following environmental triggers (injury, sepsis) [28], but its effects on increased morbidity and mortality associated with aberrant inflammatory responses are largely unknown. Additional research is needed to estimate the effect of such treatment.

2.3. Targeted (immunomodulatory) treatment

Although immunomodulatory therapy is not routinely recommended, majority of clinical trials on CRS are focused on direct influencing highly elevated pro-inflammatory cytokines (interleukin IL-1, IL-2, IL-6, IL-7, IL-10, IL-18, TNF-α, indirectly by modulation of INF-γ production or by interfering NF-κB through JAK inhibitors. If possible, it is critical to intervene prior to the initiation of CRS and severe respiratory distress mainly in patients at high risk of worsening. To increase the chances of survival of such patients, the compassionate use of available drugs is required, based on literature data and current experience of many clinicians. Patients with cytokine release syndrome secondary to viral etiology, show increased production of pro-inflammatory cytokines similar to that found in patients who develop CRS secondary to CAR-T cell therapy [29,30].

2.3.1. Anti TNF-α

The most common clinically used group of biological drugs are TNF-α blockers, but their role in treatment of cytokine storm remains unclear. Although TNF-α inhibiting agents have been reported to be effective in cytokine dysbalance, other report worsening during treatment with TNF-α inhibiting agents, the published results have been conflicting [31].

2.3.2. Anti IL-6

Tocilizumab remains the most commonly used therapy for systemic treatment of CRS. Multiple studies confirmed the correlation of peak IL-6 levels with the severity of CRS leading to the approval of tocilizumab for treatment of CRS concurrent with the approval of tisagenlecleucel, CAR T-cell therapy in non-Hodgkin lymphomas (DLBCL) [32]. Tocilizumab, IL-6 receptor-targeted monoclonal antibody has been effectively used to treat CRS in several scenarios. Since April 2020, newly opened clinical trial “Efficacy and safety of tocilizumab in the treatment of SARS-CoV-2 related pneumonia (TOSCA)” (NCT04332913) might show a rationale for those patients who develop CRS, blocking the complications caused by high levels of IL-6, and possibly preventing the development of a multi-organ failure. Two other studies recruit patients with the aim to influence CRS in hematopoietic stem cell transplantation (haplo-HSCT) (NCT03533101) and in CAR-T cell therapy pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia (NCT02906371). Other molecule which could manage CRS is siltuximab, a murine chimeric mAb which is an IL-6 antagonist. According to a survey published by special interest group of American Society for Blood and Marrow Transplantation Pharmacy, siltuximab should be considered for cases of tocilizumab-refractory CRS. The liable favour of siltuximab is its direct binding to IL-6 whereas tocilizumab binds to IL-6R which may result in increased IL-6 levels [33].

2.3.3. Anti IL-1

Perspective pathway in immunomodulatory approaches is to modulate levels of IL-1 by using anakinra or canakinumab. It is well established that an over-expression of interleukin-1 is one of the hallmarks in CRS, probably through activation of nuclear factor transcription and activator protein 1. Environmental trigger binds to TLRs which activate the formation of pro-IL-1 and activation of the inflammasome [34]. Inflammasome activation is important for the regulation of both the innate and adaptive immune mechanisms paving the way for specific immune responses. After the inflammasome activation, IL-1β is subsequently produced, which mediates the inflammation and thus contributes to cytokine storm. Shakooery et al. in 2016 [35] reported that IL-1R blockade with anakinra is associated with higher survival rate of septic patients presenting signs of cytokine storm. The safety and wide therapeutic margin of anakinra and the central role of IL-1 in the cytokine storm merit reconsideration of this therapeutic agent as a potential treatment option for CRS. This cytokine is not consistently elevated in patients with severe CRS [36], so an aspect of personalized medicine approaches should be considered. Canakinumab is a monoclonal antibody directed against IL-1β [37]. Although canakinumab is an effective treatment in SJIA, it does not appear to have a significant effect on reducing the cytokine storm.

2.3.4. Anti IL-18

IL-18 has a strong pro-inflammatory activity so inhibition of the pro-inflammatory cascade triggered by IL-18 can be a therapeutic target not only for the treatment of inflammatory diseases but also for cytokine storm. Gabay et al. published the results in open-label, multicenter study of tadekining-α, recombinant human interleukin-18 binding protein (IL-18BP) in adult-onset Still’s disease (Phase II). They concluded that IL-18 inhibition might offer another possibility of therapy within the scope of anti-cytokine treatment such as NLRC4-related macrophage activation syndrome, the etiological factor leading to clinical manifestation of CRS [38].

2.3.5. JAK inhibitors

The Janus kinases (JAKs) transduce cytokine-induced signals from specific receptors that bind a broad array of cytokines, including those involved in almost all forms of CRS. Based on their essential roles in transmitting, the JAKs might become a target for pharmacologic manipulation not only in inflammatory diseases (rheumatoid arthritis, ulcerative colitis) and in myeloproliferative disorders (myelofibrosis, polycythaemia vera) but also in the management of cytokine storm. There are several antibody-based TH17 blockades (anti IL-17, anti IL-17R and anti IL-12/23p40) available; however, the antibody-based treatment is expensive and has only a narrow spectrum of effects [39]. Therefore, treatment by JAK inhibitors is tested to restrict the pro-inflammatory function of existing TH17 cells. Treatment with the JAK1/2 inhibitor ruxolitinib significantly reduced the symptoms of disease and prolonged survival time in experimental murine model. Ruxolitinib diminished pro-inflammatory cytokine production, mitigating the cytokine-driven hyperinflammation that occurs in various cytokine release syndromes [40]. This experimental work supports the integration of JAK inhibitors such as ruxolitinib into clinical trials as a novel strategy to counteract pathological cytokine-driven tissue inflammation [41]. Since April 2020, three new, currently recruiting clinical trials are available on ClinicalTrial.gov (accessed 26 August 2020) focusing on treatment COVID-19 associated cytokine storm with ruxolitinib as monotherapy (NCT04362137, NCT04361903, NCT04354044 – see Table 1). Except for ruxolitinib, even baricitinib and fedratinib are potent and selective JAK inhibitors approved for indications in rheumatology and hematology. All three are powerful anti-inflammatory drugs that, as JAK–STAT signaling inhibitors, are likely to be effective against the consequences of the elevated levels of cytokines in various forms of CRS, not excluding viral etiology (COVID-19). Although the three candidates have similar JAK inhibitor potencies, Stebbing et al. [42] suggests, due to a high affinity for AAK1, baricitinib as the best of the group, especially given its once-daily oral dosing and acceptable side-effect profile. Two Italian
immunotherapy and adjunctive treatment in successful fight with complications related to cytokine storm after CAR-T cell therapy gives us a promise for future clinical studies.

3. Conclusion

Cytokine release syndrome is a sudden onset of almost life-threatening clinical symptomatology which can occur within diverse external or internal conditions. Early identification of rising state and multilevel course of treatment is imperative. Strictly immunologic approach is necessary mainly when considering immunomodulatory treatment. At present, the most widely used molecule for systemic treatment of CRS remains tocilizumab. Its FDA and EMA approval for the treatment of cytokine storm after CAR-T cell therapy gives us a promise for the future. The only exact knowledge about immunologic processes gives us possibilities for combination of pharmaceutical and non-pharmaceutical and adjunctive treatment in successful fight with consequences of CRS. Further work is needed to cut off the signaling pathways that lead to “cytokine storm” and to determine how these effector molecules can be most effectively targeted to help resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets and understanding of exact genetics as well as epigenetic factors that might lead to more personalized medicine approaches.

Declaration of Competing Interest

The author declares no commercial or financial conflict of interest.

Acknowledgment

I would like to thank Mgr. Branišlav Ochodnicky for his help in reviewing the English language.

References

[1] P.P. Wadia, A.R. Tambur, Yin and yang of cytokine regulation in solid organ graft rejection and tolerance, Clin Lab Med. 28 (3) (2008) 469–479, https://doi.org/10.1016/j.cll.2008.08.001, vii-viii.
[2] F. Krochinsky, F. Stolzel, S. von Bonin, G. Beutel, M. Kochanek, et al., Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group, New drugs, new toxicities: severe side effects of modern targeted and immunomodulatory therapy [55].
[3] K. Stratton, A. Ford, E. Rusch, E. Wright Clayton (Eds.), Adverse effects of vaccines: Evidence and causality, IOM (Institute of Medicine), The National Academies Press, Washington, 2012.
[4] L. Chatenoud, C. Ferrar, A. Reuter, C. Legendre, Y. Gevaert, et al., Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected], N Engl J Med 320 (1989) 1420–1421.
[5] P. Vehg, E. Erdos, E. Balogh, T. Janossy, T.G. Kovats, A comparative study on the local inflammatory and immunosuppressive activities of anti-mouse anti-lymphocyte sera, Clin Exp Immunol. 19 (2) (1973) 387–391.
[51] G. He, Q. Li, W. Li, Y. Ruan, X. Xiong, et al., Effect of ulinastatin on interleukins and pulmonary function in bypass patients: a meta-analysis of randomized controlled trials, Herz. (2018), https://doi.org/10.1007/s00059-018-4732-0.

[52] P. Zarogoulidis, N. Papanas, I. Koumias, E. Chatzaki, E. Maltezos, K. Zarogoulidis, Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases, Eur J Clin Pharmacol. 68 (5) (2012) 479–503, https://doi.org/10.1007/s00228-011-1161-x.

[53] E. Cecrdlova, K. Petrickova, L. Kolen, M. Petricek, A. Sekerkova, et al., Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes, Immunol Lett. 169 (2016) 8–14, https://doi.org/10.1016/j.imlet.2015.11.010.

[54] I. Darwish, S. Mubareka, W.C. Liles, Immunomodulatory therapy for severe influenza, Expert Rev Anti Infect Ther. 9 (7) (2011) 807–822, https://doi.org/10.1586/eri.11.56.

[55] C. Ciavarella, I. Motta, S. Valente, G. Pasquinelli, Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease, Molecules 25 (9) (2020) E2076, https://doi.org/10.3390/molecules25092076.